These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Early treatment with L-thyroxine in children and adolescents with type 1 diabetes, positive thyroid antibodies, and thyroid gland enlargement.
    Author: Kordonouri O, Hartmann R, Riebel T, Liesenkoetter KP.
    Journal: Pediatr Diabetes; 2007 Aug; 8(4):180-4. PubMed ID: 17659058.
    Abstract:
    AIM: To investigate whether early treatment with l-thyroxine may prevent deterioration of thyromegaly and progression to subclinical or clinical hypothyroidism in pediatric patients with type 1 diabetes, positive thyroid antibodies, and ultrasound abnormalities of the thyroid gland. METHODS: The development of thyroid gland volume and function in patients without L-thyroxine treatment (group A, n = 8) was assessed and compared with that in patients receiving L-thyroxine treatment (group B, n = 7) with median follow-up time of 2.0 yr (range 0.6-3.0 yr). Standard deviation score (SDS) of thyroid gland volume was calculated according to gender- and age-corresponding data. RESULTS: Median thyroid gland volume SDS at study entry was 4.8 (range 2.0-15.3) in group A and 5.6 (3.6-13.9) in group B. At follow-up, median thyroid volume SDS has increased by 0.8 (-3.9 to 6.0) at 1 yr and by 2.0 (-4.5 to 10.9) at 2 yr in group A but decreased significantly by -3.4 (-10.0 to 0.4) and -5.3 (-12.3 to -1.7) in group B, respectively. The change of thyroid gland volume was significantly different between the two groups (p = .043 and .032, respectively). In group A, three of eight patients without therapy developed subclinical hypothyroidism with thyroid-stimulating hormone elevation. CONCLUSION: These data demonstrate that treatment with L-thyroxine in patients with diabetes, positive thyroid antibodies, and elevated gland volume leads to a significant reduction of thyromegaly. Prospective randomized clinical trials are required to prove these preliminary findings.
    [Abstract] [Full Text] [Related] [New Search]